AKS-619d

AKS-619d is an investigational therapeutic Fc-fusion protein being developed by Akston Biosciences for the treatment of various cancers in dogs (canine oncology). Built on Akston's proprietary Ambifect platform, the drug is designed to target Programmed death-ligand 1 (PD-L1). PD-L1 is an immune checkpoint protein often overexpressed on the surface of tumor cells to inhibit T-cell activity and evade immune surveillance. By binding to PD-L1 and blocking its interaction with the PD-1 receptor on T-cells, AKS-619d aims to restore the immune system's ability to recognize and eliminate cancer cells. The Ambifect technology allows for the creation of potent, long-acting biologics specifically optimized for veterinary use.